All In Biotech

Drug Trial Radar · NCT07169695

A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis

Efficacy and Safety Assessment of T1695 Ophthalmic Suspension, Versus Ciclosporin Ophthalmic Emulsion, in Participants With Moderate to Severe Vernal Keratoconjunctivitis (VKC)

Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Mar 24, 2026

Primary completion

Jan 21, 2027

Study completion Jan 21, 2027

Sponsor

Lead sponsor
Laboratoires TheaIndustry
Sponsor type
Industry
First posted
Sep 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 4 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants with Moderate to Severe Vernal Keratoconjunctivitis

Conditions

  • Moderate to Severe Vernal Keratoconjunctivitis

Interventions

  • Slit Lamp ExaminationDiagnostic test

    The participant will have a slit lamp examination

  • Far Best Corrected Visual Acuity (BCVA)Diagnostic test

    The participant 's BCVA will be evaluated.

  • T1695Drug

    The participant should instill T1695.

  • CiclosporinDrug

    The participant should instill Ciclosporin.

  • Corneal fluorescein staining score on modified Oxford scaleDiagnostic test

    One drop of fluorescein will be instilled to assess the fluorescein staining score on the modified Oxford scale.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline (Day 1) at Day 29 (Week 4) in Corneal Fluorescein Staining (CFS) grade assessed by the (0-5) modified Oxford scale in the study eye.Time frame: From Day 1 to Day 29

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • M&J Institute of Ophthalmology

    Ahmedabad, India · Recruiting

  • Netralaya Super Speciality Eye Hospital

    Ahmedabad, India · Recruiting

  • Narayana Nethralaya

    Bangalore, India · Recruiting

  • L. V. Prasad Eye Institute (LVPEI)

    Hyderabad, India · Recruiting

  • Agrawal Hospital

    Jaipur, India · Recruiting

  • Regional Institute of Ophthalmology (RIO) - Kolkata

    Kolkata, India · Recruiting

  • Regional Institute of Ophthalmology, Patna

    Patna, India · Recruiting

  • PBMA'S H. V. Desai Eye Hospital

    Pune, India · Recruiting

  • Shivam Retina Clinic and Eye Hospital

    Surat, India · Recruiting

  • L V Prasad Eye Institute

    Visakhapatnam, India · Recruiting

  • Disha Eye Hospitals - Barrackpore

    Kolkata, West Bengal, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.